Quantum BioPharma announces Annual General, Special Meeting results

Quantum BioPharma announced the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9. There were shareholders represented in person or by proxy at the AGSM holding 12 class A multiple voting shares and 1,769,228 class B subordinate voting shares, representing 100% and 46.352% of the votes attached to the Class A Multiple Voting Shares and Class B Subordinate Voting Shares, respectively, with each Class A Multiple Voting Share entitling the holders thereof to 276,660 votes on all matters. Each nominee listed in the Company’s management information circular dated August 14, 2025, was elected as a director of the Company. Each director will serve until the next annual meeting of shareholders or until his or her successor is duly elected or appointed. In addition, at the AGSM, the shareholders also: re-appointed MNP LLP as the Company’s auditor and authorized the directors to fix the Auditor’s remuneration; and the holders of Class B Subordinate Voting Shares, exclusive of Class B Subordinate Voting Shares held by holders of Class A Multiple Voting Shares, passed an ordinary resolution authorizing the Board to approve, in its sole discretion, the issuance of up to an additional 56 Class A Multiple Voting Shares until the Company’s next annual meeting, as further described in the Circular